SETBP1 dysregulation in congenital disorders and myeloid neoplasms

Nicoletta Coccaro, Giuseppina Tota, Antonella Zagaria, Luisa Anelli, Giorgina Specchia and Francesco Albano _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:51920-51935. https://doi.org/10.18632/oncotarget.17231

Metrics: PDF 1890 views  |   HTML 3335 views  |   ?  


Nicoletta Coccaro1, Giuseppina Tota1, Antonella Zagaria1, Luisa Anelli1, Giorgina Specchia1 and Francesco Albano1

1Department of Emergency and Organ Transplantation (D.E.T.O.), Hematology Section, University of Bari, Bari, Italy

Correspondence to:

Francesco Albano, email: [email protected]

Keywords: SETBP1, mutation, oncogene, Schinzel–Giedion syndrome, myeloid neoplasms

Received: February 24, 2017     Accepted: March 30, 2017     Published: April 19, 2017


Myeloid malignancies are characterized by an extreme molecular heterogeneity, and many efforts have been made in the past decades to clarify the mechanisms underlying their pathogenesis.

In this scenario SET binding protein 1 (SETBP1) has attracted a lot of interest as a new oncogene and potential marker, in addition to its involvement in the Schinzel-Giedon syndrome (SGS). Our review starts with the analysis of the structural characteristics of SETBP1, and extends to its corresponding physiological and pathological functions. Next, we describe the prevalence of SETBP1 mutations in congenital diseases and in hematologic malignancies, exploring how its alterations might contribute to tumor development and provoke clinical effects. Finally, we consider to understand how SETBP1 activation could be exploited in molecular medicine to enhance the cure rate.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 17231